Evidence map›Paper›PMID 41986651›Full record

ArticleOncogene2026

PSPC1-AS2/PSPC1 axis drives STAT3-dependent CCL2 expression to promote M2 macrophage polarization and liver metastasis in gastric cancer.

Yuejiao Zhong, Xuemei Zhou, Yuan Zhou, Haoze Shi, Suo Mo, Yuting Huang, Xianfeng Cheng, Hao Chen, Li Yin

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yuejiao Zhong *Department of Medical Oncology, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, China.
Xuemei Zhou *Department of Radiation Oncology, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, China.
Yuan Zhou *Department of Hepatobiliary Surgery, Tumor Hospital Affiliated To Nantong University, Nantong Tumor Hospital, Nantong, China.
Haoze ShiDepartment of pathology, Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing, China.ORCID http://orcid.org/0000-0002-6718-9675
Suo MoClinical laboratory, Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing, China.
Yuting HuangSchool of Nursing, Nanjing Medical University, Nanjing, China.
Xianfeng ChengClinical laboratory, Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing, China. cxf1979@vip.163.com.ORCID http://orcid.org/0009-0008-6032-4978
Hao ChenDepartment of pathology, Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing, China. ch76ch@163.com.
Li YinDepartment of Radiation Oncology, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, China. yinli_2012@126.com.ORCID http://orcid.org/0009-0004-2669-4087

Funding

Nantong Science and Technology Bureau JCZ18093Science and Technology Support Program of Jiangsu Province (Jiangsu Province Science and Technology Support Program) Z2021056Science and Technology Support Program of Jiangsu Province (Jiangsu Province Science and Technology Support Program) Z2024046
6 · The paper itself

Abstract

Liver metastasis is a major cause of mortality in gastric cancer (GC), yet the underlying molecular mechanisms remain poorly understood. Long non-coding RNAs (lncRNAs) have emerged as key regulators of gene expression and cancer progression, but their roles in GC liver metastasis are not fully defined. In this study, lncRNA sequencing of primary GC tumors and matched liver metastatic tissues identified PSPC1-AS2 as significantly upregulated. Its elevated expression was further validated across multiple patient cohorts and public datasets. Functional assays demonstrated that PSPC1-AS2 promotes GC cell migration, invasion, and liver metastasis both in vitro and in vivo. Mechanistically, PSPC1-AS2 is predominantly localized in the nucleus and enhances the mRNA stability of its neighboring gene PSPC1 by recruiting the RNA-binding protein EIF4A3. The PSPC1-AS2/PSPC1 axis facilitates tumor progression and induces macrophage polarization toward the pro-tumorigenic M2 phenotype via increased CCL2 secretion. At the molecular level, PSPC1 interacts with PARP1, competitively inhibiting PARP1-mediated PARylation and dephosphorylation of STAT3, thereby sustaining STAT3 activation and promoting CCL2 transcription. Notably, neutralization of CCL2 effectively reverses PSPC1-induced M2 macrophage polarization. Collectively, these findings reveal a novel PSPC1-AS2/PSPC1/STAT3/CCL2 regulatory axis that drives GC progression and liver metastasis through remodeling of the tumor microenvironment, highlighting a potential therapeutic target for advanced gastric cancer.

Indexed as

Chemokine CCL2Liver NeoplasmsMacrophagesNuclear ProteinsRNA-Binding ProteinsSTAT3 Transcription FactorStomach NeoplasmsAnimalsCell Line, TumorCell MovementGene Expression Regulation, NeoplasticHumansMaleMiceRNA, Long NoncodingCCL2 protein, humanChemokine CCL2Nuclear ProteinsRNA-Binding ProteinsRNA, Long NoncodingSTAT3 protein, humanSTAT3 Transcription Factor

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.